Literature DB >> 23046179

Medical management for chronic atherosclerotic peripheral arterial disease.

Farzana Nawaz Ali1, Teresa L Carman.   

Abstract

The generalized term 'peripheral vascular disease' (PVD) may be used to refer to vascular disorders in any non-coronary arterial bed. The more specific term 'peripheral arterial disease' (PAD) is used to refer to a more specific process, atherosclerotic disease of the lower extremities. PAD is common. Conservative estimates suggest more than 8  million Americans may be affected by PAD. Since atherosclerosis is a systemic process, PAD should be identified as a coronary heart disease risk equivalent. However, PAD remains an under-diagnosed and under-recognized risk for cardiovascular morbidity and mortality. PAD symptoms may range from non-specific ambulatory leg complaints, to typical symptoms of intermittent claudication to critical limb ischaemia with rest pain, gangrene or ulceration. These symptoms directly impact quality of life and may affect functional capacity. There are two therapeutic goals for patients with PAD: first, to reduce the risk of cardiovascular events and second, to manage the lower extremity symptoms. This manuscript reviews the medical management of patients with PAD, briefly discussing the goals of cardiovascular risk factor modification and then focusing on pharmacological management strategies for patients with intermittent claudication and critical limb ischaemia.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23046179     DOI: 10.2165/11640810-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  78 in total

1.  Exertional leg symptoms other than intermittent claudication are common in peripheral arterial disease.

Authors:  M M McDermott; S Mehta; P Greenland
Journal:  Arch Intern Med       Date:  1999-02-22

2.  The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease.

Authors:  Eric P Brass; Richard Anthony; Frederick R Cobb; Isao Koda; Jenny Jiao; William R Hiatt
Journal:  J Am Coll Cardiol       Date:  2006-11-28       Impact factor: 24.094

3.  A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication.

Authors:  Reena L Pande; William R Hiatt; Peter Zhang; Norbert Hittel; Mark A Creager
Journal:  Vasc Med       Date:  2010-04-12       Impact factor: 3.239

4.  Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease.

Authors:  Amy M West; Justin D Anderson; Frederick H Epstein; Craig H Meyer; Hongkun Wang; Klaus D Hagspiel; Stuart S Berr; Nancy L Harthun; Arthur L Weltman; Joseph M Dimaria; Jennifer R Hunter; John M Christopher; Christopher M Kramer
Journal:  J Am Coll Cardiol       Date:  2011-08-30       Impact factor: 24.094

5.  Atherosclerotic risk factor control in patients with peripheral arterial disease.

Authors:  Thomas F Rehring; Brian G Sandhoff; Ryan S Stolcpart; John A Merenich; H Whitton Hollis
Journal:  J Vasc Surg       Date:  2005-05       Impact factor: 4.268

Review 6.  Do angiotensin converting enzyme inhibitors improve walking distance in patients with symptomatic lower limb arterial disease? A systematic review and meta-analysis of randomised controlled trials.

Authors:  Yousef Shahin; Fayyaz Mazari; Ian Chetter
Journal:  Int J Surg       Date:  2010-12-30       Impact factor: 6.071

7.  A pilot study of L-arginine supplementation on functional capacity in peripheral arterial disease.

Authors:  Roberta K Oka; Andrzej Szuba; John C Giacomini; John P Cooke
Journal:  Vasc Med       Date:  2005-11       Impact factor: 3.239

8.  Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease.

Authors:  Sergio Mondillo; Piercarlo Ballo; Riccardo Barbati; Francesco Guerrini; Tiziana Ammaturo; Eustachio Agricola; Monica Pastore; Francesco Borrello; Mirko Belcastro; Andrea Picchi; Renato Nami
Journal:  Am J Med       Date:  2003-04-01       Impact factor: 4.965

9.  Intermittent claudication: a double-blind crossover trial of pentoxifylline.

Authors:  A S Gallus; F Gleadow; P Dupont; J Walsh; A A Morley; A Wenzel; M Alderman; D Chivers
Journal:  Aust N Z J Med       Date:  1985-08

10.  Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials.

Authors:  Jeffrey S Berger; Mori J Krantz; John M Kittelson; William R Hiatt
Journal:  JAMA       Date:  2009-05-13       Impact factor: 56.272

View more
  8 in total

1.  Muscle IL1β Drives Ischemic Myalgia via ASIC3-Mediated Sensory Neuron Sensitization.

Authors:  Jessica L Ross; Luis F Queme; Elysia R Cohen; Kathryn J Green; Peilin Lu; Aaron T Shank; Suzie An; Renita C Hudgins; Michael P Jankowski
Journal:  J Neurosci       Date:  2016-06-29       Impact factor: 6.167

2.  Sensitization of group III and IV muscle afferents in the mouse after ischemia and reperfusion injury.

Authors:  Jessica L Ross; Luis F Queme; Aaron T Shank; Renita C Hudgins; Michael P Jankowski
Journal:  J Pain       Date:  2014-12       Impact factor: 5.820

3.  Long Term Stability Evaluation of Prostacyclin Released from Biomedical Device through Turbiscan Lab Expert.

Authors:  Christian Celia; Marcello Locatelli; Felisa Cilurzo; Donato Cosco; Emanuela Gentile; Daniela Scalise; Maria Carafa; Cinzia Anna Ventura; Mathias Fleury; Christelle Tisserand; Renato C Barbacane; Massimo Fresta; Luisa Di Marzio; Donatella Paolino
Journal:  Med Chem       Date:  2015       Impact factor: 2.745

4.  Sex differences in primary muscle afferent sensitization following ischemia and reperfusion injury.

Authors:  Jessica L Ross; Luis F Queme; Jordan E Lamb; Kathryn J Green; Michael P Jankowski
Journal:  Biol Sex Differ       Date:  2018-01-03       Impact factor: 5.027

5.  Enantioselective synthesis of cyclopenta[b]benzofurans via an organocatalytic intramolecular double cyclization.

Authors:  Bruno Matos Paz; Yang Li; Mathias Kirk Thøgersen; Karl Anker Jørgensen
Journal:  Chem Sci       Date:  2017-10-02       Impact factor: 9.825

6.  Drug-eluting balloon angioplasty versus uncoated balloon angioplasty for the treatment of in-stent restenosis of the femoropopliteal arteries.

Authors:  Ahmed Kayssi; Wissam Al-Jundi; Giuseppe Papia; Daryl S Kucey; Thomas Forbes; Dheeraj K Rajan; Richard Neville; Andrew D Dueck
Journal:  Cochrane Database Syst Rev       Date:  2019-01-26

7.  Interleukin 1β inhibition contributes to the antinociceptive effects of voluntary exercise on ischemia/reperfusion-induced hypersensitivity.

Authors:  Jessica L Ross; Luis F Queme; Jordan E Lamb; Kathryn J Green; Zachary K Ford; Michael P Jankowski
Journal:  Pain       Date:  2018-02       Impact factor: 7.926

8.  Study of pentoxifylline effects on motility and viability of spermatozoa from infertile asthenozoospermic males.

Authors:  Aliye Ghasemzadeh; Farid Karkon-Shayan; Solmaz Yousefzadeh; Mohammad Naghavi-Behzad; Kobra Hamdi
Journal:  Niger Med J       Date:  2016 Nov-Dec
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.